Bone marrow impairment during early [Lu-177]PSMA-617-Radioligand Therapy: hematotoxicity or tumor progression? - Kind, F.; Michalski, K.; Yousefzadeh-Nowshahr, E.; Meyer, P.T.; Mix, M.; Ruf, J. (Nuklearmedizin - NuclearMedicine, 2022)